Skip to main content
SpringerLink
Log in

Nelfinavir: a new protease inhibitor for HIV infection

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Perry CM, Benfield P. Nelfinavir. Drugs 1997 Jul; 54(1): 81–7

    Article  PubMed  CAS  Google Scholar 

  2. Gathe Jr JC. Nelfinavir: a viewpoint. Drugs 1997 Jul; 54(1): 88

    Article  Google Scholar 

  3. Breckenridge A. Nelfinavir: a viewpoint. Drugs 1997 Jul; 54(1): 88

    Article  Google Scholar 

  4. Markowitz M, Conant M, Hurley A, et al. Phase I/II dose range-finding study of the HIV protease inhibitor AG1343 [abstract]. 35th Int Conf Antimicrob Agents Chemother 1995 Sep 17–20 Program Addendum: 8

  5. Conant M, Markowitz M, Hurley A, et al. A randomized phase II dose range-finding study of the HIV protease inhibitor Viracept® as monotherapy in HIV positive patients [abstract]. 11th International Conference on AIDS. 1996 Jul 7–12; Vancouver, 286–7

  6. Moyle G, Youle M, Chapman S, et al. A phase II dose escalation study of the Agouron protease inhibitor AG 1343 [abstract]. 35th Int Conf Antimicrob Agents Chemother. 1995 Sep 17–20 Program Addendum: 8

  7. Gathe JJ, Burkhardt B, Hawley P, et al. A randomized phase II study of Viracept®, a novel HIV protease inhibitor, used in combination with stavudine vs. stavudine alone [abstract]. 11th International Conference on AIDS. 1996 Jul 7–12; Vancouver, 25

  8. Clinical trials update. Scrip 1996 Jun 18(2138): 20

    Google Scholar 

  9. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society — USA Panel. JAMA 1997 Jun 25;277: 1962–9

    Article  Google Scholar 

  10. Markowitz M, Winslow D, Cao Y, et al. Triple therapy with nelfinavir (Viracept® in combination with AZT and 3TC in 12 antiviral-naive subjects chronically infected with HIV-1 [abstract]. Tenth International Conference on Antiviral Research. 1997 Apr 6–11; Atlanta

  11. Henry K, Lamarca A, Myers R, et al. The safety of VIRACEPT® (nelfinavir mesylate) in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with d4T or AZT/3TC [Poster]. 4th Conference on Retroviruses and Opportunistic Infections. 1997 Jan 22–26; Washington, DC

  12. Connett S. First dual protease inhibitor combination shows promise. Bioworld Today 1996 Jul 11; 7:1,3

    Google Scholar 

  13. Prescott L. Redefining the approach to treating HIV infection. Inpharma 1996 Aug 30; 1052: 13–4

    Google Scholar 

  14. Pedneault L, Elion R, Adler M, et al. Stavudine (d4T), didanosine (ddl), and nelfinavir combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot study [abstract]. 4th Conference on Retroviruses and Opportunistic Infections. 1997 Jan 22–26; Washington, DC

  15. Agouron Pharmaceuticals Inc. Nelfinavir mesylate Prescribing Information. La Jolla, California, USA, 1993

    Google Scholar 

  16. Deeks SG, Smith M, Holodniy M, et al. HIV-1 Protease Inhibitors. A Review for Clinicians. JAMA 1997; 277(2) 145–153

    Article  PubMed  CAS  Google Scholar 

  17. Agouron Pharmaceuticals Inc. Agouron reports positive results from pivotal clinical trials of Viracept®. Media Release: 1997 Jan 23

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nelfinavir: a new protease inhibitor for HIV infection. Drugs Ther. Perspect 10, 7–9 (1997). https://doi.org/10.2165/00042310-199710120-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199710120-00003

Keywords

Search

Navigation